Related Experiment Video

Updated: Jun 17, 2026

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice

Jennifer A Westwood1, Nicole M Haynes, Janelle Sharkey

  • 1Authors' Affiliations: Cancer Immunology Research Program, Peter MacCallum Cancer Centre; Departments of Microbiology and Immunology and Pathology, University of Melbourne, Melbourne, Australia; and Laboratory of Liposome Research, Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 10, 2009
PubMed

Insights

This study shows that combining CpG 1826 and anti-CD137 antibody eradicates tumors in mice by activating immune cells. Depleting macrophages enhanced this antitumor effect, leading to complete tumor rejection and long-term immunity.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Cancer immunotherapy aims to harness the immune system to fight tumors.
  • Combining immunomodulatory agents can create synergistic antitumor effects.
  • Understanding the roles of different immune cells is crucial for optimizing cancer therapy.

Purpose of the Study:

  • To evaluate the antitumor activity of a novel combination of Toll-like receptor agonist CpG 1826 and anti-CD137 antibody.
  • To elucidate the mechanisms underlying the combination's therapeutic efficacy.
  • To investigate the roles of various immune cells and components in mediating antitumor responses.

Main Methods:

  • Treatment of established tumors in mouse models with CpG 1826 and anti-CD137 antibody.
  • Use of gene-deficient mice and cell-depleting antibodies to determine mechanistic insights.
  • Analysis of immune cell activation, expansion, and function.

Main Results:

  • The combination therapy eradicated tumors in a significant proportion of mice.
  • CD8(+) T cells, natural killer cells, and interferons (IFNs) were critical for the antitumor effect.
  • Depletion of macrophages enhanced therapy, leading to 100% tumor rejection, a novel finding.
  • Long-term survivors developed resistance to tumor rechallenge, indicating immunologic memory.
  • B cells were found to be essential for the induction of antitumor immunologic memory.

Conclusions:

  • The combination of CpG 1826 and anti-CD137 antibody demonstrates potent antitumor activity.
  • This combination therapy effectively stimulates multiple immune system components against cancer.
  • The findings support the development of this novel immunotherapy for cancer treatment.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...